【摘要】 目的 以阿米卡星为对照评价奈替米星治疗下呼吸道感染的临床有效性及安全性。方法 共入选病例132例，可评价疗效者102例，其中试验组(奈替米星)与对照组(阿米卡星)分别为52例与50例。安全性评价入选病例113例，两组分别为56例与57例。给药方法试验组每次200mg，每日1次，对照组每次200mg，每日2次，两组疗程均为7～14天。结果 试验组与对照组的临床有效率分别为84.61%与64.00%，细菌清除率分别为90.91%与66.67%，敏感菌百分率分别为93.18%与71.43%，听力下降发生率分别为1.79%与15.79%。以上结果经

    统计学处理两组差异有显著性。结论 奈替米星为治疗下呼吸道感染的安全、有效的抗菌药物。

    【关键词】 随机对照试验；下呼吸道感染；奈替米星；阿米卡星；治疗结果

    A randomized clinical study of netilmicin versus amikacin in treatment of lower respiratory tract infections

    ZHOU Hai-ying,SUN Shu-ming, HU Zhi-xiong.

    Jinshan Hospital, Fudan University, Shanghai 200540,China

    【Abstract】 Objective To evaluate the efficacy and safety of netilmicin(NET) compared with amikacin(AMK) in the treatment of lower respiratory tract infections. Methods A total of 132 patients enrolled in the study. 102 patients were evaluated for efficacy (NET 52, AMK 50) and 113 patients were evaluated for safety (NET56,AMK57). NET was administered once a day for 7～14 days at a daily dose of 200mg and AMK was administered twice a day for 7～14 days at a daily dose of 400mg.Results The overall clinical efficacy rates of NET and AMK were 84.61% and 64.00%, respectively. The bacteriological clearance rates of NET and AMK were 90.91% and 66.67%,respectively. The bacterial susceptibility rates of NET and AMK were 93.18% and 71.43%,respectively. The incidence of hearing loss for NET and AMK were 1.79% and 15.79%, respectively. The study demonstrated that there were statistical differences between the two groups with respect to clinical efficacy, bacterial clearance and incidence of hearing loss. ......